DOSE MATTERS: PROGNOSTIC ROLE OF TIME-WEIGHTED RUXOLITINIB EXPOSURE IN MYELOFIBROSIS (SIE 2026) - Oct 6, 2026 - Abstract #DP214; Pres time: Sep 22, 2026; 06:30 PM - 07:30 PM; Location: AREA POSTER; "Our data suggest that long-term prognosis may be driven by the feasibility of maintaining dose intensi- ty (> 20 mg/day) during early phases of treatment, which are the most critical to achieve a SR. Therefore, a proactive management of AEs and treatment-emergent cytopenias to sustain dosage rather than reducing RUX dosage (at least in the early phases) may be important to maximize RUX clini- cal benefit."
Biomarker • Hematological Disorders • Myelofibrosis
|
|
A. Laganà; E. Scalzulli; I. Carmosino; M. L. Bisegna; M. Gherardini; D. Kasmi; A. L. Faccini; C. Andriola; M. Martelli; M. Breccia
|